Veru (VERU) was gaining over 37% in value after saying its oral treatment sabizabulin showed positive results in a phase 3 study with COVID-19 patients at high risk of acute respiratory distress syndrome. The company said that the treatment showed a 55% relative reduction in deaths and was well tolerated.
Matinas BioPharma Holdings (MTNB) was up more than 14% after the company and BioNTech (BNTX) announced an exclusive research agreement to evaluate the combination of mRNA formats and Matinas' proprietary platform technology.
Affimed (AFMD) was climbing past 14% after saying a phase 1/2 study of its innate cell engager AFM13 combined with cord blood-derived natural killer cells in patients with relapsed Hodgkin and non-Hodgkin lymphomas showed a 100% objective response rate.
|--US Natural Gas Stocks Rise by 82 Bln Cubic Feet in...|
|Morgan Stanley Adjusts Franklin Resources' Price Tar...|
|Morgan Stanley Adjusts Invesco's Price Target to $17...|
|Morgan Stanley Adjusts T. Rowe Price Group's Price T...|
|Morgan Stanley Adjusts Price Target on Bed Bath & Be...|